Institute for problems of cardiovascular diseases
Institute for problems of cardiovascular diseases
Ang Cardio Balance Kapseln ay isang epektibo at ligtas na paraan para mapanatili ang kalusugan ng puso at pababain ang presyon ng dugo. Dahil sa kanilang natural na sangkap at mataas na bisa, nagiging maaasahang katuwang sila sa paglaban sa mataas na presyon ng dugo at sa pagpapabuti ng kalidad ng buhay.
ЧИТАТЬ ДАЛЕЕ ...
The Institute for problems of cardiovascular diseases: On the way to a healthier Tomorrow Heart and circulatory diseases are the leading causes of death. According to the world health organization, millions of people die each year from diseases of the circulatory system, often preventable fates. In the midst of this challenge, the Institute for problems of cardiovascular diseases as an important instance of the medical research and patient care. That research facility founded, the Institute quickly became a national and international centre of excellence. Its main goal is to explore the causes of heart and circulatory diseases, to develop innovative treatment methods, and prevention of these diseases. The researchers of the Institute are working on several areas: Investigation of genetic factors that increase the risk for heart disease. The development of new drugs against atherosclerosis and heart failure. Optimization of methods for early detection of blood tests to imaging procedures. Studies on the effect of lifestyle factors: exercise, nutrition, Stress. Use of artificial intelligence for prediction of cardiac risk. A particular concern of the Institute is the education of the population. Regular information events, brochures, leaflets and Online campaigns to encourage people to keep your heart health in mind. Prevention begins in the mind, says Prof. Dr. Elke Winter, Director of the Institute. A healthy lifestyle, regular testing and Knowledge of risk factors can save lives. In addition, the Institute supports the training of young Doctors and scientists. Through exchange programs with international partner institutes valuable knowledge and experiences are shared. The results speak for themselves: thanks to the work of the Institute, a large number of new therapy approaches in clinical practice. The survival rates after heart attacks are increased, and the quality of life of patients with chronic heart disease has improved significantly. The Institute is widely explored, and new hurdles, it remains his Mission is clear: cardiovascular disease is not only to understand better, but to prevent you, one day, as much as possible. Because every healthy heart is a victory for the medicine and for all of us.
People have long used Hawthorne berries for treating high bp, heart issues, and cholesterol levels. A number of Clinical research conclude that it improves cardiovascular function, shortness of breath, and fatigue. In another study, 1200 mg hawthorn extract or placebo was taken by hypertension patients for 16 weeks. Those who were taking hawthorn extract had a significant decrease in blood pressure than the other group taking a placebo. Institute for problems of cardiovascular diseases. People have long used Hawthorne berries for treating high bp, heart issues, and cholesterol levels. A number of Clinical research conclude that it improves cardiovascular function, shortness of breath, and fatigue. In another study, 1200 mg hawthorn extract or placebo was taken by hypertension patients for 16 weeks. Those who were taking hawthorn extract had a significant decrease in blood pressure than the other group taking a placebo.
Heart Tachycardia Vascular Disorders
Valsartan for high blood pressure
The rehabilitation centre for cardiovascular diseases
http://atom-pro.com/articles/12097-dizziness-in-cardiovascular-diseases.html
https://demo.atlantisweb.ru/articles/14962-cardiovascular-inherited-diseases.html
I have two stents inserted in my heart and have been dealing with nerve-wracking irregular heartbeat my whole life. I decided to give Cardio Balance a try, and I thank God for it! Just after using it for a couple of weeks, my irregular heart beating became normal. I feel more ALIVE, young, and energetic.
Monoclonal antibodies against high blood pressure: A new approach in the therapy High blood pressure, or hypertension, is one of the most common cardiovascular disease worldwide and is recognized as a major risk factor for heart attacks, strokes and kidney disease. Despite a variety of available medications, the effective control of blood pressure remains at a part of patients is a challenge. In recent years, monoclonal antibodies have proved to be promising new therapeutic promise proven approach. Basics of monoclonal antibodies Monoclonal antibodies (mAb; engl. monoclonal antibodies) are artificially produced proteins that bind specifically to certain antigens. Their use in medicine has proven itself in particular in Oncology and autoimmune therapy. The high specificity makes it possible to selectively influence the molecular mechanisms involved in the pathogenesis of diseases. Mechanisms of blood pressure regulation and potential target structures Blood pressure regulation is carried out via a complex neuro-humoral systems, including: the Renin‑Angiotensin‑aldosterone‑System (RAAS), Sympathetic nervous system activity, and the Regulation of sodium ausschie extension by peptides such as natriuretic peptides. One of the most promising starting points for monoclonal antibody inhibition of Angiotensin‑converting sketching that is emitted enzyme 2 (ACE2), or the Modulation of Endothelin‑1, a strong vasoconstrictor is. Other possible targets are: PCSK9 (Proprotein‑Convertase Subtilisin/Kexin type 9), which may also have an influence on blood pressure parameters, Interleukin‑6 (IL‑6) and other proinflammatory cytokines that are involved in vascular dysfunction. Previous Research Results In preclinical studies, monoclonal antibodies, directed against Endothelin‑1 were able to demonstrate a significant reduction in blood pressure in hypertensive animal models. A Phase II study with an Anti‑IL‑6 Receptor antibody demonstrated in patients with rheumatoid Arthritis and concomitant hypertension, a moderate but significant reduction in systolic blood pressure by an average of 8-12 mmHg. Another promising agent is an antibody against Angiotensin II, which blocks binding to the AT1 Receptor. In comparison to classical AT1‑Receptor‑blockers (ARB) provides this approach, a longer duration of action and may be a lower Rate of side effects. Challenges and perspectives Despite the promising results, challenges still exist: high production costs compared to conventional blood pressure potential immunological reactions against foreign proteins, the need for long-term studies on efficacy and safety. However, monoclonal antibodies are opening up new opportunities, particularly for patients with resistant hypertension or comorbid disorders such as chronic renal insufficiency or Diabetes mellitus. Conclusion Monoclonal antibodies represent an innovative approach for the treatment of high blood pressure. Due to their high specificity and long-lasting effect, you could play in the future an important role in the individualized therapy of hypertension. Further clinical studies are required to assess their full potential, and your safety. Would you like me to make a certain section in more detail, or to add further Details to one aspect?